|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Theseus Pharmaceuticals, Inc. (THRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
42,504,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Theseus Pharmaceuticals is engaged in the discovery, development and commercialization of targeted therapies for cancer patients. Co.'s development programs are designed to address drug resistance mutations in key driver oncogenes. Co.'s product candidate, THE-630, is a pan-variant inhibitor of all main classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumours. Co.'s second program is focused on inhibitors of epidermal growth factor receptor (EGFR), that are active against C797S, the common EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,659,864 |
2,557,866 |
| Total Buy Value |
$0 |
$0 |
$5,006,586 |
$9,584,210 |
| Total People Bought |
0 |
0 |
3 |
7 |
| Total Buy Transactions |
0 |
0 |
3 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gordon Carl L |
Director |
– • • |
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
| Gordon Carl L |
Director |
– • • |
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
| Dahms Bradford D. |
Chief Financial Officer |
• – – |
2021-12-21 |
4 |
B |
$10.15 |
$20,000 |
D/D |
1,970 |
1,970 |
2.74 |
- |
|
| Clackson Timothy P |
President and CEO |
• • – |
2021-12-21 |
4 |
B |
$9.76 |
$25,381 |
D/D |
2,600 |
348,530 |
2.81 |
- |
|
| Ariad Pharmaceuticals Inc |
10% Owner |
– – • |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,615,427 |
1,615,427 |
|
- |
|
| Gordon Carl L |
Director |
– • • |
2021-10-12 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
499,150 |
2.25 |
- |
|
| Gordon Carl L |
Director |
– • • |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
16,213,668 |
436,650 |
|
- |
|
| Orbimed Genesis Gp Llc |
10% Owner |
– – • |
2021-10-12 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
499,150 |
1.5 |
- |
|
| Orbimed Genesis Gp Llc |
10% Owner |
– – • |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
16,213,668 |
436,650 |
|
- |
|
| Paster Anne-Mari |
Former 10% owner |
– – – |
2021-10-12 |
4 |
B |
$16.00 |
$3,000,000 |
D/D |
187,500 |
711,479 |
2.44 |
- |
|
| Paster Anne-Mari |
Former 10% owner |
– – – |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
D/D |
523,979 |
523,979 |
|
- |
|
| Rock Springs Capital Llc |
10% Owner |
– – • |
2021-10-12 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
599,320 |
1.5 |
- |
|
| Rock Springs Capital Llc |
10% Owner |
– – • |
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
436,649 |
87,329 |
|
- |
|
| Shakespeare William |
See Remarks |
• – – |
2021-10-12 |
4 |
B |
$16.00 |
$10,000 |
D/D |
625 |
388,949 |
2.74 |
- |
|
| Shakespeare William |
See RemarksOfficer |
• – – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
388,324 |
|
- |
|
| Clackson Timothy P |
President and CEOOfficer |
• • – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
345,930 |
|
- |
|
| Dalgarno David |
Chief Technical OfficerOfficer |
• – – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
388,324 |
|
- |
|
| Rivera Victor |
Chief Scientific OfficerOffice |
• – – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
388,324 |
|
- |
|
| Dukes Iain D. |
Director |
– • – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
388,324 |
|
- |
|
46 Records found
|
|
Page 2 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
